2-O-[2-O-[2-O-[2-O-(2-O-Alpha-D-Glucopyranosyl-1-Deoxy-Beta-D-Fructofuranose-1-Yl)-1-Deoxy-Beta-D-Fructofuranose-1-Yl]-1-Deoxy-Beta-D-Fructofuranose-1-Yl]-1-Deoxy-Beta-D-Fructofuranose-1-Yl]-1-Deoxy-Beta-D-Fructofuranose-1-Yl Beta-D-Fructofuranoside

Brief Introduction

This product is mainly used as pharmaceutical and chemical intermediates.

83534-39-8

CAS:83534-39-8

Alias

More Information

Pngase F; N-Glycosidase F; Native Almonds Glycopeptidase A; Pngase A; Glycopeptide N-Glycosidase; N-Oligosaccharide Glycopeptidase; N-Glycanase; Glycopeptidase; Jack-bean Glycopeptidase; Peptide-N4-(N-Acetyl-|A-Glucosaminyl)Asparagine Amidase; Pngase

Brief Introduction

N-glycosidase F (PNGase F) is an amidohydrolase, cloned from the Peaceful Space Station Elizabeth and recombinantly expressed in E. coli E. coli, that cleaves asparagine-linked high-mannose, hybrid and complex oligosaccharide glycoproteins. The cleavage site of PNGase F is the amide bond between N-acetylglucosamine (GlcNAc) and asparagine residues on the inner side of the glycoprotein, and at the same time, the aspartyl on the protein after enzymatic hydrolysis is converted to aspartic acid. This product is often used for complete deglycosylation of antibodies and related proteins.

Aducanumab

CAS:1384260-65-4

Alias

More Information

Aducanumab (USAN); D10541; Aducanumab (Genetical Recombination) (JAN); BIIB037; BIIB-037

Brief Introduction

Aducanumab is a human monoclonal antibody that is being studied for the treatment of Alzheimer's disease (AD). It is being developed by Biogen Inc., which licensed the drug candidate from Neurimmune, its discoverer.The antibody targets aggregated forms of β-amyloid (Aβ) in the hopes of reducing its buildup.

Rilonacept

CAS:501081-76-1

Brief Introduction

It is a soluble interleukin receptor fusion protein developed by Regeneron Corporation, which can block the inflammatory response signaling pathway of interleukin. The researchers first conducted a 6-week small-sample clinical trial of linacept in the treatment of chronic gout, and found that linacept can effectively control inflammation, reduce pain and inflammation on joints, and have mild adverse reactions. A single subcutaneous injection of linacept 320 mg reduces pain and adverse effects of acute gout attacks compared with the highest dose of a non-steroidal anti-inflammatory drug (indomethacin, 50 mg three times a day for 3 days) the occurrence of the reaction.

Finerenone

CAS:1050477-31-0

Molecular Formula:C21H22N4O3

Alias

More Information

Finerenone (BAY 94-8862); (4S)-4-(4-Cyano-2-Methoxyphenyl)-5-Ethoxy-2,8-Dimethyl-1,4-Dihydro-1,6-Naphthyridine-3-Carboxamide; BAY94-8862; BAY 94-8862

Brief Introduction

Fenneridone is a new type of mineralocorticoid receptor antagonist, which can delay the progression of chronic kidney disease. Some people may be aware of two other mineralocorticoid receptor antagonists: diuretics, antihypertensive drugs, spironolactone, and eplerenone. Non neridone is their sibling, and the third generation of mineralocorticoid receptor antagonist just came out after them.

1
···
24
25
26
27
28
29
30
31
32

Inquiry (

/ 10

)

Clear All